KLK3 and breast carcinoma: Therefore, PSA immunoreactivity in breast tumors could be a useful tool in predicting the prognosis and response to adjuvant therapy in female breast cancer patients [15-18].To test this hypothesis, we investigated the PSA immunoreactivity in breast cancer associated with relapse-free and overall survival in breast cancer patients.